Transient MOG antibody seroconversion associated with immunomodulating therapy

Mult Scler Relat Disord. 2020 Jan:37:101420. doi: 10.1016/j.msard.2019.101420. Epub 2019 Sep 28.

Abstract

Immunoglobulin G (IgG) autoantibodies targeting myelin oligodendrocyte glycoprotein (MOG) have recently been associated with autoimmune CNS demyelination. We present the case of a 35-year-old patient who was seronegative for MOG-IgG (as confirmed by means of three independent immunoassays) during two corticosteroid-responsive attacks of brainstem encephalitis and optic neuritis, respectively, but turned positive for MOG-IgG under treatment with interferon-beta (IFN-beta), which was commenced 6 months after onset of the first attack. MOG-IgG serum levels declined after therapy was switched to glatiramer acetate. The fact that seroconversion was first observed under treatment with IFN-beta is in accordance with previous evidence suggesting a role of IFN-beta in disease exacerbation in antibody-mediated disorders.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aquaporin 4 / immunology
  • Autoantibodies / blood
  • Autoantibodies / pharmacology*
  • Encephalitis / complications
  • Encephalitis / drug therapy
  • Humans
  • Immunoglobulin G / blood
  • Immunomodulation / immunology*
  • Myelin-Oligodendrocyte Glycoprotein / immunology*
  • Neuromyelitis Optica / complications
  • Neuromyelitis Optica / diagnosis
  • Neuromyelitis Optica / drug therapy
  • Optic Neuritis / diagnosis
  • Optic Neuritis / immunology
  • Optic Neuritis / therapy*
  • Seroconversion / drug effects
  • Seroconversion / physiology*

Substances

  • Aquaporin 4
  • Autoantibodies
  • Immunoglobulin G
  • Myelin-Oligodendrocyte Glycoprotein